Search

Royalty Pharma PLC (Class A)

Закрыт

СекторЗдравоохранение

58.44 -0.9

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

57.74

Макс.

59.03

Ключевые показатели

By Trading Economics

Доход

-589M

-295M

Продажи

44M

674M

P/E

Средняя по отрасли

31.747

56.432

Прибыль на акцию

1.32

Дивидендная доходность

1.55

Рентабельность продаж

-43.713

Сотрудники

100

EBITDA

-387M

176M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+11.29% upside

Дивиденды

By Acuity

Дивидендная доходность

Средняя по отрасли

1.55%

2.27%

Следующий отчет о доходах

4 нояб. 2026 г.

Дата следующей выплаты дивидендов

9 дек. 2026 г.

Следующая эксдивидендная дата

13 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.2B

34B

Предыдущая цена открытия

59.34

Предыдущая цена закрытия

58.44

Новостные настроения

By Acuity

15%

85%

17 / 339 Рейтинг в Healthcare

Royalty Pharma PLC (Class A) График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

15 сент. 2026 г., 23:16 UTC

News

Royalty Pharma announced a $7.5 million donation to Blood Cancer United. Shares are lower in after-market trading amid rising Treasury yields.

14 сент. 2026 г., 20:07 UTC

Royalty Pharma PLC shares are higher today, reflecting a modest gain since Friday. Broader market concerns over rising crude oil prices may be influencing sentiment.

11 сент. 2026 г., 20:08 UTC

Royalty Pharma PLC shares are lower today, pulling back from earlier gains amid broader market dynamics and inflation pressures influencing Federal Reserve policy.

10 сент. 2026 г., 23:46 UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing a rise since Thursday's close, though still below the 20-day moving average.

9 сент. 2026 г., 20:07 UTC

News

Royalty Pharma shares lower today, following a decline after Novartis' trial failure. Analysts suggest the drop may be overdone amid stable royalty expectations.

8 сент. 2026 г., 21:01 UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting broader market dynamics despite no specific company news identified.

5 сент. 2026 г., 00:01 UTC

News

Royalty Pharma PLC shares fell in after-market hours following the failed Phase 3 trial of pelacarsen, impacting its funding agreement with Ionis.

4 сент. 2026 г., 22:14 UTC

Royalty Pharma PLC shares are trading lower during after-market hours, breaking a trend of higher daily closes. No specific news was identified for the decline.

3 сент. 2026 г., 23:05 UTC

Royalty Pharma PLC shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

2 сент. 2026 г., 23:06 UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting a slight decline since Wednesday's close, despite earlier recovery attempts.

1 сент. 2026 г., 20:09 UTC

Royalty Pharma PLC is rising as strength in the pharmaceuticals sub-sector boosts shares. The stock remains near its one-month high despite a recent pullback.

31 авг. 2026 г., 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting positive market sentiment. The stock remains near the upper end of its one-month trading range.

28 авг. 2026 г., 20:07 UTC

Royalty Pharma PLC shares are lower today amid broader market declines and rising U.S. Treasury yields, reflecting ongoing volatility in the pharmaceuticals sector.

27 авг. 2026 г., 23:11 UTC

Royalty Pharma PLC shares are higher in after-market trading, supported by a favorable performance backdrop and positioning above the 20-day moving average.

26 авг. 2026 г., 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, currently above their 20-day moving average and near the upper end of their one-month range.

25 авг. 2026 г., 20:07 UTC

Royalty Pharma PLC shares are higher today, continuing an upward trend since Monday. Lower Treasury yields are supporting investor sentiment in the market.

24 авг. 2026 г., 20:06 UTC

Royalty Pharma PLC shares are near unchanged as market sentiment is influenced by rising oil prices and geopolitical tensions from new U.S. sanctions against Iran.

21 авг. 2026 г., 19:26 UTC

Royalty Pharma PLC shares are higher, reflecting a broader rebound in U.S. stocks amid economic uncertainties and rising inflation. The asset remains above its 20-day moving average.

20 авг. 2026 г., 23:11 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline from earlier in the session amid mixed broader market sentiment.

19 авг. 2026 г., 20:02 UTC

Royalty Pharma PLC shares are higher today, driven by strong investor interest in pharmaceuticals and unusually high market volume during regular trading hours.

18 авг. 2026 г., 23:21 UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing an upward trend from previous sessions. No specific news was identified for this movement.

17 авг. 2026 г., 19:36 UTC

Royalty Pharma PLC shares are trading higher during Monday's session, recovering from an earlier dip and remaining above the 20-day moving average.

15 авг. 2026 г., 00:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a routine decline since Friday's close amid mixed global equity market performance.

14 авг. 2026 г., 19:46 UTC

Event
Social Media

Royalty Pharma PLC declared a $0.235 per share dividend today, with shares advancing since Thursday's close and near the upper end of their one-month range.

13 авг. 2026 г., 20:02 UTC

Social Media

Royalty Pharma PLC shares are lower amid a $100 million royalty agreement with Zealand Pharma for rusfertide rights, reflecting unusual trading activity.

12 авг. 2026 г., 20:01 UTC

Royalty Pharma PLC shares are higher today, supported by a broader market trend of gains since Tuesday. The stock is seeing unusually high trading volume.

11 авг. 2026 г., 19:56 UTC

Royalty Pharma PLC shares are trading higher, reaching a session high earlier today. No specific news was identified to explain the price movement.

10 авг. 2026 г., 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting notable strength and unusual activity since Monday's close, with no specific news identified.

7 авг. 2026 г., 23:41 UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting notable gains since Friday's close amid a shift toward a dovish monetary policy outlook.

6 авг. 2026 г., 23:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, moving above Thursday's close, despite remaining below the 20-day moving average.

Сравнение c конкурентами

Изменение цены

Royalty Pharma PLC (Class A) Прогноз

Целевая цена

By TipRanks

11.29% рост

Прогноз на 12 месяцев

Средняя 65.714 USD  11.29%

Максимум 70 USD

Минимум 62 USD

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для Royalty Pharma PLC (Class A) на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

7 ratings

7

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

17 / 339Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat